We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+48.65%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$840M
AUM Growth
+$194M
Cap. Flow
+$27.1M
Cap. Flow %
3.23%
Top 10 Hldgs %
96.44%
Holding
16
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$36.9M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$9.74M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.85B
$149M 17.76%
5,858,262
– –
IRON icon
2
Disc Medicine
IRON
$2.66B
$148M 17.58%
2,555,172
-190,163
-7% -$9.74M
DYN icon
3
Dyne Therapeutics
DYN
$3.37B
$131M 15.66%
9,885,449
– –
THRD
4
DELISTED
Third Harmonic Bio
THRD
$120M 14.25%
10,907,859
– –
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
$111M 13.23%
7,608,394
– –
KRRO icon
6
Korro Bio
KRRO
$174M
$53.6M 6.39%
+1,119,292
New +$36.9M
JBIO
7
Jade Biosciences
JBIO
$1.09B
$46.1M 5.5%
58,264
– –
VIGL
8
DELISTED
Vigil Neuroscience
VIGL
$19.7M 2.35%
5,836,874
– –
REPL icon
9
Replimune Group
REPL
$1.21B
$17.7M 2.11%
2,098,300
– –
GBIO
10
DELISTED
Generation Bio
GBIO
$13.7M 1.63%
827,948
– –
IMA
11
ImageneBio Inc
IMA
$57M
$9.89M 1.18%
418,182
– –
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$8.39M 1%
359,251
– –
TECX
13
Tectonic Therapeutic
TECX
$532M
$6.18M 0.74%
378,448
– –
DNTH icon
14
Dianthus Therapeutics
DNTH
$5.66B
$2.46M 0.29%
236,979
– –
XLO icon
15
Xilio Therapeutics
XLO
$59.5M
$1.52M 0.18%
197,096
– –
SPRO icon
16
Spero Therapeutics
SPRO
$65.2M
$1.49M 0.18%
1,013,438
– –

Similar funds

AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
FSCM
Front Street Capital Management Missoula, Montana $881M AUM 86.5% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
TAM
TCP Asset Management Columbus, Ohio $882M AUM 21.79% 1-Year Est. Return
FFG
Fiduciary Financial Group San Rafael, California $882M AUM 23.98% 1-Year Est. Return
MWA
Meridian Wealth Advisors Austin, Texas $880M AUM 30.15% 1-Year Est. Return
1IA
1834 Investment Advisors Milwaukee, Wisconsin $883M AUM 23.82% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $880M AUM 44.18% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Atlas Venture Life Science Advisors held 16 positions worth $840M, up 30% from $646M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Atlas Venture Life Science Advisors deployed $27.1M of net new capital in Q4 2023, opening 1 new position. Its largest new stake was Korro Bio: 1,119,292 shares worth $53.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Disc Medicine, an estimated $9.74M trimmed.

  • Atlas Venture Life Science Advisors's largest Q4 2023 buy was Korro Bio: 1,119,292 shares worth $53.6M.
  • Atlas Venture Life Science Advisors's biggest Q4 2023 reduction was Disc Medicine, cutting an estimated $9.74M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 96% of its $840M portfolio in Q4 2023.
  • Atlas Venture Life Science Advisors opened 1 new position and closed 0 in Q4 2023.
  • Atlas Venture Life Science Advisors's portfolio value rose 30% quarter-over-quarter to $840M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.